The idea that a mouse brain or a rat brain or any other animal brain can predict how a human brain would react to a particular drug—it's not credible. Yet up until this point, this has been the only solution that pharma has had available to them.
28bio today announced the Nexon™ neurotechnology platform—a major advancement in understanding human brain function. The platform integrates tissue engineering, neural interfacing and AI to engineer human brains at-scale and replicate complex neurological processes.
AxoSim has appointed Stuart Gibb as VP of Sales and Marketing. With over 20 years of experience, Stuart will help accelerate AxoSim's commercial growth in drug discovery and development.
AxoSim names Alif Saleh as CEO to advance commercialization. Former CEO Dr. Lowry Curley becomes Chief Scientific Officer to drive scientific innovation.
Serial Entrepreneurs Dale Pfost and David Weiner Bring Broad Expertise as AxoSim Expands Its Leadership in Human Organoid Technologies Designed to Make Neurological R&D Faster, More Efficient and More Successful
Combines Three Leading Live Biomimetic Organoid Platforms Designed to Make R&D for Neurological Diseases Faster, More Efficient and More Successful. AxoSim Gains Expert Scientific Team and Advanced R&D and Manufacturing Capabilities "Upriver" in Minnesota to Augment Its "Downriver" Facilities in New Orleans
As Vyant Bio continues its wind-down, the neuroscience research assets of its subsidiary StemoniX have officially been picked up by AxoSim, a New Orleans-based drug discovery biotech.
AxoSim has entered a definitive agreement to acquire Vyant Bio's StemoniX microBrain™ platform, uniting top-tier organoid technologies to accelerate neurological drug discovery.
